TITLE:
HuMax-CD20 in Chronic Lymphocytic Leukemia

CONDITION:
Chronic Lymphocytic Leukemia

INTERVENTION:
HuMax-CD20

SUMMARY:

      The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a
      treatment for Chronic Lymphocytic Leukemia.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Chronic Lymphocytic Leukemia

          -  Circulating lymphocytes above a specific level

          -  Circulating lymphocytes showing certain markers

        Exclusion Criteria:

          -  Previous treatment with rituximab or alemtuzumab within 6 months prior to enrollment
             in study.

          -  Previous stem cell transplantation.

          -  Received any of the following treatments within 4 weeks prior to entering this trial:
             A) Anti-cancer therapy, B) Glucocorticoids unless less than 10 mg per day, C)
             Radiotherapy.

          -  HIV positivity.

          -  Hepatitis B or hepatitis C.

          -  Other cancerous diseases, except certain skin cancers and cervix cancer.

          -  Certain serious medical conditions, including kidney or liver disease, some
             psychiatric illnesses, and stomach, heart, hormonal, nerve or blood diseases.

          -  Participation in another trial with a different new drug 4 weeks prior to enrollment
             in study.

          -  Current participation in any other clinical study.

          -  Pregnant or breast-feeding women.

          -  Women of childbearing age who are unable or unwilling to use adequate contraception.
      
